Our investigations in preclinical models of gastric cancer demonstrate that [89Zr]Zr-DFO-avelumab has a specific affinity for PD-L1 binding in NCIN87 cancer cells that express low to moderate levels of PD-L1. Here, CD274 is linked to gastric cancer.